Actively Recruiting

Phase Not Applicable
FEMALE
ID06864520

Evaluation of Beneficial Effects of a GABA-Based Product on Menopausal Syndrome Symptoms

Led by Ospedale Policlinico San Martino · Updated on 2025-03-07

112

Participants Needed

1

Research Sites

4 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are studying whether a food supplement based on gamma-aminobutyric acid (GABA) and Melissa extract can help reduce climacteric symptoms experienced during menopause, such as hot flashes, sleep problems, and mood swings. The trial also aims to evaluate the safety of this supplement compared to a placebo, which contains no active ingredients. This study focuses on women experiencing physiological or iatrogenic menopause with significant symptoms as measured by the Greene Index. Participants will be randomly assigned to one of four groups receiving either the GABA supplement or placebo in two different dosages. The supplements are taken as tablets daily—either three capsules (one at lunch and two before bedtime) or two capsules (one at lunch and one before bedtime)—for 12 weeks. Neither participants nor researchers know who receives the supplement or placebo during the study. During the trial, participants will attend clinic visits on days 7, 37, 97, and a final visit to complete symptom diaries and questionnaires assessing hot flashes, sleep quality, anxiety, depression, and quality of life. Researchers will track changes in climacteric symptoms using the Greene Climacteric Scale and other validated tools. The study will monitor participant satisfaction and collect safety information throughout the 3-month treatment period.

CONDITIONS

Brief Title

Evaluation of the Beneficial Effects of a Product Containing Γ-aminobutyric Acid (GABA) on Climacteric Syndrome Disorders

Who Can Participate

FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Female with physiological or medically induced menopause (amenorrhea for at least 12 months or 6 months with FSH 60 40 IU/L)
  • Greene Index score of 15 or higher indicating menopausal symptoms
Not Eligible

You will not qualify if you...

  • Declines consent to participate in the study
  • Used hormone replacement therapy in the last 3 months
  • Used phytotherapeutic products in the last 3 months
  • Received acupuncture in the last 3 months
  • Has uncontrolled hyperthyroidism or hypothyroidism
  • Experiencing acute endocrine diseases
  • Has major psychiatric disorders
  • Addicted to opioids or alcohol
  • Has glaucoma
  • Has active liver disease
  • Currently using antidepressants, benzodiazepines, or other neuroactive drugs
  • Known allergy to any component of the study treatment

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - 12 weeks

Participants take the study product or placebo daily for 12 weeks while completing questionnaires and hot flash diaries at scheduled visits.

4 visits (in-person) over 12 weeks

Trial Site Locations

Total: 1 location

1

Ospedale San Martino

Genova, Italia, Italy, 16132

Actively Recruiting

Loading map...

Research Team

A

ANGELO CAGNACCI

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

4

Similar Trials

A Feasibility Study of Biometric Measurements Via Wearable S...

Prostate Cancer

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here